FORMULATION DEVELOPMENT OF AMORPHOUS DISPERSIONS - Pharmaceutical Amorphous Solid Dispersions - page 397

32. Food and Drug Administration (2012) Guidance for Industry. Q8(R2). Pharmaceutical
Development .
33. Food and Drug Administration, CDER (2012) Draft Guidance for Industry and Review Staff:
Target Product Pro le-Strategic Development Tool .
34. Food and Drug Administration, CDER (2012) Guidance for Industry. Q8(R2). Pharmaceuti-
cal Development .
35. ICH (2005) Q9: Quality Risk Management . Available at http://www.ich.org/ leadmin/

Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf .
36. ICH (2008) Q10: Pharmaceutical Quality Systems . Available at http://www.ich.org/leadmin/
Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf .
37. ICH (2009) Q8(R2): Pharmaceutical Development . Available at http://www.ich.org/leadmin/
Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf .
38. Kwong, A.D., Kauffman, R.S., Hurter, P., and Mueller, P. (2011) Discovery and development
of telaprevir: an NS3-4a protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Nat. Biotechnol. , 29(11):993-1003.
39. Lavanchy, D. (2009) The global burden of hepatitis C. Liver Int. , 29(Suppl. 1):74-81.
40. Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., and Bell, B.P. (2006) The
contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary
liver cancer worldwide. J. Hepatol. , 45(4):529-538.
41. Hoofnagle, J.H. (2002) Course and outcome of hepatitis C. J. Hepatol. , 36(5 Suppl. 1):

S21-S29.
42. Brass, V., Moradpour, D., and Blum, H.E. (2006) Molecular virology of hepatitis C virus
(HCV): 2006 update. Int. J. Med. Sci. , 3(2):29-34.
43. Lawrence, S.P. (2000) Advances in the treatment of hepatitis C. J. Adv. Int. Med. , 45:65-105.
44. Kolykhalov, A.A., Mihalik, K., Feinstone, S.M., and Rice, C.M. (2000) Hepatitis C virus-
encoded enzymatic activities and conserved RNA elements in the 3 ´ nontranslated region are
essential for virus replication in vivo . J. Virol. , 74(4):2046-2051.
45. Cui, Y., Murphy, M., Dinehart, K., Hurter, P., and Connelly, P. (2006) Pharmaceutical
compositions. U.S. Patent Application 20060089385.
46. Bittorf, K.J., Katstra, J.P., and Gaspar, F. (2010) Fluidized spray drying. U.S. Patent
Application 20100011610.
47. SAS Publishing (2009) .

48. ICH (2003) Q1A(R2): Stability Testing of New Drug Substances and Products . Available at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/
ucm073369.pdf.

JMP8: Statistics and Graphics Guide